NUTX Stock Analysis: Buy, Sell, or Hold?
NUTX - Nutex Health Inc. Common Stock
$193.90
-2.02 (-1.03%)
▼
5d:
+2.84%
30d:
+38.02%
90d:
+48.49%
WAIT
LOW Confidence
Analysis Updated: Aug 27, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When NUTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NUTX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NUTX shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$233.34
Based on 2.9% avg growth
INTRINSIC VALUE TODAY
$144.89
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NUTX is currently trading at $193.90, which is considered extended relative to its 30-day fair value range of $151.35 to $187.96. The stock's valuation (Forward PE: 6.7) is in line with its historical norms (7.0). Remarkably, the market is currently pricing in an annual earnings decline of 1.3% over the next few years. This pessimistic expectation contrasts with the company's recent 95.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, NUTX is in a strong uptrend. Immediate support is located at $176.55, while resistance sits at $200.00.
Market Sentiment: NUTX scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $276.00 (+42.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NUTX is in a strong uptrend. Immediate support is located at $176.55, while resistance sits at $200.00.
Market Sentiment: NUTX scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $276.00 (+42.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$151.35 -
$187.96
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
28.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (23/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 42.3% below Wall St target ($276.00)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$151.35 -
$187.96
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$176.55
Resistance Level
$200.00
Current Trend
Strong Uptrend
Technical data as of
Aug 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.73
Wall Street Target
$276.00
(+42.3%)
Revenue Growth (YoY)
-13.6%
Earnings Growth (YoY)
95.9%
Profit Margin
21.2%
Valuation Discount vs History
-1.3% cheaper
PE vs Historical
6.7 vs 7.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.3%
(market-implied from PE analysis)
1-Year Target
$191.38
(-1%)
2-Year Target
$188.89
(-3%)
3-Year Target
$186.44
(-4%)
3-Yr Target (if PE normalizes)
(PE: 7→7)
$194.03
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 1.9%)
$611.57
(+215%)
Base:
(SPY PE: 6.7, Growth: 1.9%)
$204.96
(+6%)
Bear:
(PE: 5.7, Growth: 1.9%)
$174.21
(-10%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (7x PE), but valuation improves significantly next year (7x PE) as earnings recover.
Trailing PE: 7.29 | Current EPS (TTM): $26.86
Bull Case
$231.30
(+19%)
Analyst growth 7.3%, PE expands to 8.0
Base Case
$210.27
(+8%)
Market implied 7.3%, PE stable at 7.3
Bear Case
$133.23
(-31%)
Severe decline -20.0%, PE contracts to 6.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.7 to 7.0
Stabilization Target:
$201.80
(+4.1%)
PE Expansion Potential:
+4.1%
Share & Embed Analysis
Last updated: August 27, 2026 9:19 PM ET
Data refreshes hourly during market hours. Next update: 10:19 PM
Data refreshes hourly during market hours. Next update: 10:19 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NUTX showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Frank E Jaumot
BUY
150 shares
2026-03-20
Warren Hosseinion
BUY
252 shares
2026-03-19
Kelvin Spears
BUY
10 shares
2026-03-17
Top Rated Medical Care Facilities Stocks
Top-rated stocks in Medical Care Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
THC
Tenet Healthcare Corpora… |
STRONG BUY
22 analysts |
$282 | 46 HOLD |
|
HCA
HCA Healthcare, Inc. |
BUY
25 analysts |
$451 | 43 HOLD |
|
EHC
Encompass Health Corp |
STRONG BUY
12 analysts |
$148 | 46 HOLD |
|
ADUS
Addus HomeCare Corporati… |
STRONG BUY
11 analysts |
$135 | 47 HOLD |
|
SGRY
Surgery Partners Inc |
STRONG BUY
12 analysts |
$19 | 55 HOLD |
